- Convalescent plasma plus standard care yields no reduction in 30-day mortality or other outcomes in severe COVID-19 pneumonia.
Why this matters
- Convalescent plasma treatment in severely ill patients with COVID-19 may need re-evaluation.
- 228 patients received convalescent plasma and 105 a placebo treatment.
- Median age: 62 (interquartile range [IQR], 52-72) years.
- Median time, symptom onset to enrollment: 8 (IQR, 5-10) days.
- Most had hypoxia.
- Infused convalescent plasma median titer: 1:3200 (IQR, 1:800-1:3200) total SARS-CoV-2 antibodies.
- At day 30:
- No significant difference in clinical outcomes (ordinal scale): OR, 0.83 (P=.46).
- Mortality: 10.96% convalescent plasma vs 11.43% placebo.
- Risk difference: −0.46 (95% CI, −7.8 to 6.8) percentage points.
- Median time to hospital discharge: 13 (IQR, 8-30) days with convalescent plasma vs 12 (IQR, 7-30) days with placebo.
- ICU admission: 53.9% receiving convalescent plasma vs 60% receiving placebo.
- Ventilatory support: 26.8% convalescent plasma vs 22.9% placebo.
- No significant differences in overall (OR, 1.21; 95% CI, 0.74-1.95) or serious adverse events (1.40; 0.78-2.51).
- Double-blind, placebo-controlled, multicenter study assessing convalescent plasma treatment vs placebo in patients hospitalized with severe COVID-19 pneumonia in Argentina.
- Funding: No external funding.
- Limited generalizability.
- Inability to measure earlier treatment effect.
- Missing confounders.